As its director, Manusis outlines the facility’s role in delivering advanced, personalized solutions to improve vision and ...

From laser vision correction to adjustable lens implants, the Center for Refractive Solutions at New York Eye and Ear ...

Eyestem has announced the completion of its phase 1 study for its investigational retinal pigment epithelium (RPE) cell ...

A look at current therapies, clinical trial results, patient education, and emerging options for managing this progressive ...

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...

Assistive devices empower patients with central vision loss to regain independence, enhancing daily activities and reducing ...

To conduct the study, the investigators obtained data on coffee consumption from genome‐wide association studies (GWAS) and ...

Ocular Therapeutix showcases innovative retinal disease treatments at the Clinical Trials Summit 2025 in Las Vegas, featuring ...

The center aims to optimize patients' vision with a range of cataract and corneal refractive procedures and minimize reliance ...

Ocugen has announced the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) amendment to ...

Aldeyra had received 2 complete response letters (CRL) from the FDA in April 2025 and November 2023 for past submissions.

Ophthalmology Times connects eye care professionals with surgery, imaging, gene therapy, & diagnostic advances to enhance ...